Osiris Therapeutics, based in Columbia, Md., completed its clinical study on the effectiveness of Grafix versus EpiFix, according to Street Insider.
Grafix is Osiris Therapeutics' cryopreserved placental membrane wound allograft, and EpiFix is a dehydrated Human Amnion/Chorion Membrane allograft manufactured by Marietta, Ga.-based MiMedx. A total of 79 patients with 101 wounds were identified for study analysis: 39 patients with 55 wounds received EpiFix and 40 patients with 46 wounds received Grafix.
Here are five points:
1. The proportion of complete wound closure was 63 percent for the Grafix group and 18.2 percent for the EpiFix group.
2. The mean baseline surface area for closed wounds was 9.4 cm2 in the Grafix group and 2.1 cm2 in the EpiFix group.
3. The mean baseline for closed wounds was 10.3 cm3 in the Grafix group and 0.55 cm3 in the EpiFix group.
4. For wounds that did not reach complete closure during the study period, a mean 43 percent surface area reduction and a mean 40 percent reduction in volume was recorded for Grafix-treated wounds versus a mean 73 percent increase in surface area and a 136 percent increase in volume for EpiFix-treated wounds.
5. Researchers concluded Grafix closed more wounds with surface areas that were over four times greater in size and 19 times greater in volume when compared to EpiFix.